

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 920522-905350	SERIAL NO. 09/831,422
LIST OF DOCUMENTS CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT REMON	
MAY 27 2004 U.S. PATENT & TRADEMARK OFFICE		FILING DATE MAY 4, 2001	GROUP 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	No
AL							
AM							
AN							
AO							
AP							

OTHER PRIOR ART (Including Author, Title, Date Pertinent Pages, Etc.)

SH	AQ	S.R. Bechard and J.C. Leroux, Drug Development and Industrial Pharmacy (1992) 18: 1927-1944, entitled "coated pelletized dosage form: effect compaction on drug release"
	AR	T.E. Beckert et al., International Journal of Pharmaceutics (1996) 143: 13-23, entitled "compression of enteric coated pellets to disintegrating tablets"
	AS	M. Celik and L. Maganti, Drug Development and Industrial Pharmacy (1994) 20: 3151-3173, entitled "formulation and compaction of microspheres"
	AT	R. Bodmeier, European Journal of Pharmaceutics and Biopharmaceutics (1997) 43: 1-8, entitled "tableting of coated pellets"
	AU	S.A. Altaf et al., Drug Development and Industrial Pharmacy (1999) 25: 635-642, entitled "Bead compacts: evaluation of rapidly disintegrating nonsegregating compressed bead formulations"
	AV	M. El-Mahdi et al., J. Macroencapsulation (2000) 17: 133-144, entitled "tableting of coated ketoprofen pellets"
	AW	L.A. Felton et al., S.T.P. Pharma sciences (1997) 6: 457-462, entitled "compaction properties of individual nonpareil beads coated with an acrylic resin copolymer"
	AX	G.F. Palmieri et al., S.T. P. Pharma sciences (1996) 6: 118-121, entitled "drug release from compressed Eudragit RS30D coated beads"
↓	AY	J.J. Torrado and L.L. Augsburger, International Journal of Pharmaceutics (1994) 106: 149-155, entitled "effect of different excipients on the tableting of coated particles"
SH	AZ	K.G. Wagner et al., S.T. P. Pharma sciences (2000) 10: 327-334, entitled "pellet-containing tablets: examination of distribution and deformation behaviour"

EXAMINER: *Sharon Howard* DATE CONSIDERED: *3/4/05*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TRADE NAME Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/831,422
(use as many sheets as necessary)		Filing Date	July 24, 2001
		First Named Inventor	Remon
		Art Unit	1615
		Examiner Name	Joynes
		Attorney Docket Number	920522-905350
Sheet	1	of	1
RECEIVED JAN 02 2004 FAX CENTER 1600/2930			

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>TJG</i>		Kydonicus, "Treatise on Controlled Drug Delivery", Marcel Dekker, Inc, NY, 1992, pp 255, 284 - 295	

Examiner Signature		Date Considered	03/08/05
-----------------------	---	--------------------	----------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

1 Applicant's unique citation designation number (optional). **2** Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.